Genetic characteristics and pathogenicity of human hepatitis E virus in Nanjing, China

Table 1 Clinical data of patients with hepatic failure

Patient No.	Sex	Age (yrs)	TBIL (μmol/L)	DBIL (μmol/L)	ALT (U/L)	AST (U/L)	PA (g/L)	ALB (g/L)	CHE (U/L)	PT (s)	PTA (%)
1II III	Male	23	507.4	442.9	183	390	30	26.1	1.6	19	34.7
2III III	Male	61	590.9	481.2	779	787	12	25	1.2	14.5	46.4
3I	Male	69	179.2	136.7	5056	4754	45	34.6	3.3	16.9	34.2
4III III	Female	21	636.4	437.5	355	611	12	31.8	1.1	65.7	4.3
5III III	Female	44	993.5	775.4	166	451	29	25	0.9	20.1	31.8
6III	Male	45	711.4	603.4	409	209	30	28.4	1.4	16.6	43
7III III	Male	57	639.9	494.2	2100	2820	9	33.9	1.7	28.2	18.9
8I	Female	58	443.1	302.5	689	1493	15	27.8	3.1	21.4	23.8
9III III	Male	36	759.8	541.9	319	278	27	29.7	1.7	25.3	18.4
10IIII	Male	79	506.8	428.7	329	548	4	30	1.4	15.7	38.9

I ascites, II dead, III hepatic encephalopathy; patient number 1, 5, 6, 7, 9 and 10 with underlying chronic liver disease, such as chronic hepatitis B, autoimmune hepatitis, alcoholic hepatitis. Patient number 4, 6, 7, 8 and 10 were positive for hepatitis E virus (HEV) RNA. Patient number 1, 2, 4, 6, 8, 9 and 10 were positive for anti-HEV IgM, and patient number 3, 4, 5, 7 and 8 were positive for anti-HEV IgG. All biochemical indices of liver function were recorded at peak level during treatment at our hospital. Because some patients were treated at other hospitals at early period of illness, the biochemical indices of liver function, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may not represent the actual peak level. TBIL: Total bilirubin; DBIL: Direct bilirubin; PA: Pre-albumin; ALB: Albumin; CHE: Cholinesterase; PTA: Prothrombin time activity; PT: Prothrombin time.